title: Reversible coma associated with prolonged high-dose phenobarbital therapy in bilateral Sturge-Weber syndrome.
abstract: High-dose phenobarbital therapy is an effective treatment for refractory status epilepticus in children. The advantages of this therapy include milder adverse effects without limits for maximal phenobarbital levels or doses during the initial phase of treatment. However, little is known about the safety of continuing the treatment. We describe an infant with intractable epilepsy associated with bilateral Sturge-Weber syndrome who became comatose after 1(2/3) months of high-dose phenobarbital treatment. The patient regained consciousness as serum phenobarbital concentration decreased to below 40 microg/mL. The progression and recovery were also documented by electroencephalogram and brainstem auditory evoked potentials. The present case suggests that prolonged high-dose phenobarbital therapy may cause cerebral and brainstem dysfunction in patients with severe cerebrovascular diseases. The underlying baseline metabolic and perfusion deficit related to the disease can precipitate the neurological complication during long-term high-dose phenobarbital therapy.
authors: Department of Pediatrics, Ehime Prefecture Central Hospital, Matsuyama City, Ehime Prefecture, Japan. hirwaka@hotmail.com
authors: Hiroyuki
authors: H
authors: Wakamoto
authors: Yasuko
authors: Y
authors: Nakamura
authors: Tomohiro
authors: T
authors: Ebihara
authors: Kiriko
authors: K
authors: Tokuda
authors: Hiromitsu
authors: H
authors: Ohmori
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D015984:Causality; D002561:Cerebrovascular Disorders / Q000150:complications / Q000503:physiopathology; D003128:Coma / Q000139:chemically induced* / Q000503:physiopathology; D003243:Consciousness / Q000187:drug effects / Q000502:physiology; D000075202:Contraindications; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004569:Electroencephalography / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D004827:Epilepsy / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects / Q000502:physiology; D005260:Female; D007839:Functional Laterality / Q000502:physiology; D006801:Humans; D007223:Infant; D010634:Phenobarbital / Q000008:administration & dosage* / Q000009:adverse effects*; D020127:Recovery of Function / Q000502:physiology; D013341:Sturge-Weber Syndrome / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000927:Anticonvulsants; D010634:Phenobarbital